KR860004060A - 티에닐 축합 피라졸 유도체의 제조방법 - Google Patents

티에닐 축합 피라졸 유도체의 제조방법 Download PDF

Info

Publication number
KR860004060A
KR860004060A KR1019850008256A KR850008256A KR860004060A KR 860004060 A KR860004060 A KR 860004060A KR 1019850008256 A KR1019850008256 A KR 1019850008256A KR 850008256 A KR850008256 A KR 850008256A KR 860004060 A KR860004060 A KR 860004060A
Authority
KR
South Korea
Prior art keywords
pyrazole derivatives
compound
condensed pyrazole
preparing
alkyl
Prior art date
Application number
KR1019850008256A
Other languages
English (en)
Other versions
KR900003496B1 (ko
Inventor
스스무 다까다 (외 4)
Original Assignee
요시또시 가즈오
시오노기 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시또시 가즈오, 시오노기 세이야꾸 가부시끼가이샤 filed Critical 요시또시 가즈오
Publication of KR860004060A publication Critical patent/KR860004060A/ko
Application granted granted Critical
Publication of KR900003496B1 publication Critical patent/KR900003496B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

티에닐 축합 피라졸 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. 하기 일반식(II)의 화합물을 염기 또는 산으로 고리화하여 하기 일반식(Ia)의 화합물을 수득하고, 화합물(Ia)를 탈에스테르화 한후, 탈카르복실화 함을 특징으로 하는 하기 일반식(Ic)의 화합물의 제조방법.
    (상기 식중 R1및 R2는 각각 수소, 알킬, 알콕시카르보닐, 카르복시, 할로겐, 니트로 또는 트리플루오로메틸이거나, R1및 R2는 함께 알킬렌을 형성할 수 있으며, X는 수소, 알킬, 알콕시, 할로겐 또는 히드록시이고, Y는 메틴 또는 질소이며, A는 이탈기이고, R은 알킬이다)
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850008256A 1984-11-05 1985-11-05 티에닐 축합 피라졸 유도체의 제조방법 KR900003496B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP233511 1984-11-05
JP233511/1984 1984-11-05
JP59233511A JPS61112075A (ja) 1984-11-05 1984-11-05 チエニルピラゾロキノリン誘導体

Publications (2)

Publication Number Publication Date
KR860004060A true KR860004060A (ko) 1986-06-16
KR900003496B1 KR900003496B1 (ko) 1990-05-21

Family

ID=16956169

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850008256A KR900003496B1 (ko) 1984-11-05 1985-11-05 티에닐 축합 피라졸 유도체의 제조방법

Country Status (8)

Country Link
US (1) US4690930A (ko)
EP (1) EP0182165B1 (ko)
JP (1) JPS61112075A (ko)
KR (1) KR900003496B1 (ko)
CA (1) CA1269983A (ko)
DE (1) DE3572358D1 (ko)
ES (1) ES8701173A1 (ko)
GB (1) GB2166439B (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814450A (en) * 1984-07-09 1989-03-21 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
US4826854A (en) * 1986-11-25 1989-05-02 Ciba-Geigy Corporation Certain cycloalka-(b)-pyrazolo(3,4-d)-pyridin-3-one derivatives
EP0478964A1 (en) * 1990-09-06 1992-04-08 Shionogi Seiyaku Kabushiki Kaisha Pyrazoloquinoline derivatives
US5442062A (en) * 1991-10-24 1995-08-15 The Upjohn Company Imidazole derivatives and pharmaceutical compositions containing the same
ID16283A (id) * 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
GB9713707D0 (en) * 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
WO1999064425A1 (en) * 1998-06-09 1999-12-16 Neurogen Corporation Substituted thienocycloalkylpyrazoles: dopamine receptor subtype specific ligands
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US20030129186A1 (en) 2001-07-25 2003-07-10 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
SE0202461D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
EP1653914A4 (en) 2003-08-12 2008-10-29 3M Innovative Properties Co COMPOUNDS CONTAINING OXIME SUBSTITUTED IMIDAZO STRUCTURE
MXPA06002199A (es) 2003-08-27 2006-05-22 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi.
JP2007504269A (ja) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
AU2004278014B2 (en) 2003-10-03 2011-04-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CN1906192A (zh) 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
MXPA06005910A (es) 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
PT1889198E (pt) 2005-04-28 2015-03-06 Proteus Digital Health Inc Sistema fármaco-informático
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2166853B1 (en) * 2007-06-08 2014-05-28 Dart Neuroscience (Cayman) Ltd Therapeutic pyrazolonaphthyridine derivatives
JP2010529144A (ja) * 2007-06-08 2010-08-26 ヘリコン・セラピューティクス・インコーポレーテッド 治療用ピラゾロキノリン尿素誘導体
WO2008154438A1 (en) * 2007-06-08 2008-12-18 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline derivatives
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
US8486946B2 (en) 2009-02-23 2013-07-16 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
WO2011049731A1 (en) 2009-10-21 2011-04-28 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
US8653079B2 (en) 2011-08-15 2014-02-18 Merck Sharp & Dohme Corp. Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0022078B1 (de) * 1979-06-21 1984-07-25 Ciba-Geigy Ag Pyrazolochinoline, Verfahren zu ihrer Herstellung, und pharmazeutische Präparate enthaltend diese Verbindungen
US4312870A (en) * 1979-06-21 1982-01-26 Ciba-Geigy Corporation Pyrazoloquinolines
US4524146A (en) * 1982-12-08 1985-06-18 Ciba-Geigy Corporation Certain -2-heterocycle substituted pyrazoloquinolines
US4479955A (en) * 1983-01-10 1984-10-30 Ciba-Geigy Corporation Heterocycle-fused pyrazolo[3,4-d]pyridin-3-ones as benzodiazepine receptor modulators
FR2549833B1 (fr) * 1983-07-26 1985-11-08 Roussel Uclaf Derives de la pyrazolo /4,3-c/ cinnolin-3-one, leurs sels, procede de preparation, application a titre de medicaments, compositions les renfermant et produits intermediaires

Also Published As

Publication number Publication date
US4690930A (en) 1987-09-01
KR900003496B1 (ko) 1990-05-21
JPS61112075A (ja) 1986-05-30
DE3572358D1 (de) 1989-09-21
JPH0370706B2 (ko) 1991-11-08
EP0182165B1 (en) 1989-08-16
ES8701173A1 (es) 1986-12-01
CA1269983A (en) 1990-06-05
GB8527227D0 (en) 1985-12-11
GB2166439A (en) 1986-05-08
ES548534A0 (es) 1986-12-01
EP0182165A1 (en) 1986-05-28
GB2166439B (en) 1988-08-03

Similar Documents

Publication Publication Date Title
KR860004060A (ko) 티에닐 축합 피라졸 유도체의 제조방법
KR850003890A (ko) 1H-이미다조[4,5c]-퀴놀린-4-아민의 제조방법
KR860003210A (ko) 알킬설폰 아미도 페닐알킬 아민의 제조 방법
SE8004194L (sv) 1-bensylimidazolderivat
SE8105240L (sv) Teofyllin- och teobrominderivat
ES557198A0 (es) Un procedimiento para la preparacion de nuevos derivados de ciclopenta(d)pirimidina
SE8703169L (sv) 1-(4-aminofenyl)-4-metyl-7,8-metylendioxi-3,4-dihydro-5h-2,3-bensodiazepin, syraadditionssalter derav samt forfarande for framstellning av densamma
KR840005101A (ko) 2-퀴놀린유도체의 제조방법
PT81545B (pt) Processo para a preparacao de compostos 5-aloquil-1-fenil-2-piperazino-alquil-pirazolin-3-ona
KR830004320A (ko) 퀴나졸린 유도체의 제조방법
KR830004210A (ko) 2-아미노-3-벤조일-페닐아세트아미드 및 환상 동족체
AU575972B2 (en) 3- aminocarbonylmethoxy - 5 - phenylpyrazole derivatives
KR900700103A (ko) 항-알레르기성 점안제
DE3574969D1 (de) Aetheroxidderivate von zyklopropylphenolen.
ATE83481T1 (de) Fuenfgliedrige heterocyclische derivate von n'substituiertenn,n'-diacylhydrazinen.
KR860008983A (ko) 4- 벤조일-1- 알킬(알켄일) 피라졸의 제조방법
KR840006238A (ko) 신규 α-아릴-α-피리딜알카노인산 유도체의 제조방법
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법
KR870004038A (ko) 제초제 화합물의 제조방법
KR840001160A (ko) 벤조디옥산-이미다졸린 유도체의 제조방법
KR830010090A (ko) 아닐린 유도체의 제조방법
KR830006176A (ko) 치환된 펜옥시-아미노프로판올 유도체의 제조방법
KR840009102A (ko) 치환된 이소퀴놀린 유도체의 제조방법
KR830005188A (ko) 혈당강하성 구아닐 아미딘의 제조방법
KR830004256A (ko) 치환된 3,6-비스(아미노알콕시) 아크리딘류의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19951227

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee